Triple-positives Antiphospholipid-Syndrom bei SLE auf dem Boden eines Kabuki-Syndroms

• Literatur

• 1 Rosina S, Chighizola CB, Ravelli A, Cimaz R. Pediatric Antiphospholipid Syndrome: from Pathogenesis to Clinical Management. Curr Rheumatol Rep 2021; 23 (02) 10 PMID: 33511497 PMCID: PMC7843475
• 2 Mormile I, Granata F, Punziano A. et al Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It. Biomedicines 2021; 9: 132 https://doi.org/10.3390/biomedicines9020132
• 3 Adam MP, Hudgins L, Hannibal M. Kabuki Syndrome In: Adam MP, Feldman J, Mirzaa GM et al., eds. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle, 1993–2024 Im Internet: https://www.ncbi.nlm.nih.gov/books/NBK1116/?term=Kabuki+Syndrome Stand: 15.09.2022
• 4 Tektonidou MG. Antiphospholipid Syndrome Nephropathy: From Pathogenesis to Treatment. Front Immunol 2018; 9: 1181
• 5 Yun Z, Duan L, Liu X. et al An update on the biologics for the treatment of antiphospholipid syndrome. Front Immunol 2023; 14: 1145145
• 6 Sevim E, Willis R, Erkan D. Is there a role for immunosuppression in antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program 2019; 2019 (01) 426-432 PMID: 31808842
• 7 Sciascia S, Rubini E, Radin M. et al Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab. Ann Rheum Dis 2018; 77: 1693-1695
• 8 Erton ZB, Leaf RK, de Andrade D. et al Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”). Lupus 2022; 31 (14) 1770-1776